News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Invitation to investor meeting 1st October 2024, 2:00 pm (CET)
23 September 2024
Dr Piotr Iwanowski appointed as Chief Medical Officer and Board Member of Molecure
1 August 2024
Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs
31 July 2024
Molecure has confirmed the in vitro activity of another molecule binding to a new mRNA target within the mRNA discovery platform
12 June 2024
Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway
21 May 2024
Molecure has published its financial report for the first quarter of 2024. The company is progressing, as anticipated, the next steps in the development of its clinical and pre-clinical programmes
17 May 2024
Events & Presentations
Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada
27 February 2020
ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA
4 September 2019
EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018
17 September 2018